Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Phase I Study of Recombinant Human Nerve Growth Factor Injection in Healthy Chinese Volunteers on Safety, Tolerability and Pharmacokinetics: Randomized, Double-blind, Placebo-controlled, Single / Multiple Dose

NCT04232332 is registered in ClinicalTrials.gov with Beijing Tongren Hospital as lead sponsor.

NCT NCT04232332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04232332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Phase I Study of Recombinant Human Nerve Growth Factor Injection in Healthy Chinese Volunteers on Safety, Tolerability and Pharmacokinetics: Randomized, Double-blind, Placebo-controlled, Single / Multiple Dose
Lead sponsor
Beijing Tongren Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
December 26, 2019
Completion date
March 31, 2022
Enrollment
86 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

injury of optic nerve